T-Cell Lymphomas Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The global T-Cell Lymphoma (TCL) market was valued at $956 million across the eight major pharmaceutical markets (8MM) in 2020. The market is projected to grow at a CAGR of more than 6% during the forecast period. The introduction of 14 new pipeline agents and label expansions for currently approved agents are key drivers of this market growth.
TCL is a rare type of cancer that forms in T-cells and is either indolent (slow-growing) or aggressive. TCL either develops in lymphoid tissues such as the lymph nodes and spleen, or other organs (gastrointestinal tract, liver, nasal cavity, and skin). TCL is broadly separated into cutaneous TCL (CTCL) and peripheral TCL (PTCL). CTCL are cancers of the skin while PTCL is a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. PTCL could be nodal such as in the lymph nodes and spleen, or extranodal such as in the gastrointestinal tract and nasal cavity. Anaplastic large-cell lymphoma (ALCL) is a major subtype that can occur in both CTCL and PTCL.
Global TCL market overview
For more insights on this report, download a free report sample
What are the market dynamics in the TCL market?
The major drivers of growth in the TCL market during the forecast period include the approval of 14 new late-stage pipeline agents, decreased reliance on generic chemotherapy for certain subtypes, and label expansion of currently marketed products in new markets. The main strategies employed by pharma companies to capture a share of the TCL market include bringing same-in-class drugs into new markets where the mechanism of action (MOA) was previously unavailable, testing novel or existing MOAs in a TCL subtype-specific fashion, and focusing on new/under-researched targets.
Several market-changing events are expected in 2020-30, most of which are anticipated in Japan and the US. This event is forecast to double the total market size of TCL by 2030. Patent expiries across the standard of care will negatively affect total sales due to generic and biosimilar competition, but that will be largely offset by new agents entering the market.
What is the country-level outlook of the TCL market?
The US had the highest share in the TCL market in 2020 followed by the 5EU countries, Japan, and China.
The US dominance is primarily attributed to a high number of eligible patients, the use of agents with higher prices, and the early marketing authorization of agents that are still not approved in other countries. The very low incidence of PTCL in Japan certainly contributes to this small, relative to its population, market share. The relative lack of currently marketed agents in China and the numerous late-stage pipeline drugs aimed specifically at the Chinese market is responsible for this impressive market growth.
Global TCL market, by countries
For more country insights, download a free report sample
Who are the key players in the TCL market?
Some of the key players in the TCL market are 4SC, Acrotech Biopharma, Affimed, Bristol Myers Squibb, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Genor Biopharma, and Innate Pharma.
Market report scope
Market size (Year – 2020) | $956 million |
Growth rate (CAGR) | >6% |
Forecast period | 2020-2030 |
Key countries | The US, 5EU countries, Japan, and China |
Key players | 4SC, Acrotech Biopharma, Affimed, Bristol Myers Squibb, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Genor Biopharma, and Innate Pharma. |
Scope
- Overview of T-cell lymphoma including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline T-cell lymphoma market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting T-cell lymphoma therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
- Analysis of the current and future market competition in the global T-cell lymphoma therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global T-cell lymphoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T-cell lymphoma market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track drug sales in the global T-cell lymphoma therapeutics market from 2020 to 2030.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Acrotech Biopharma
Affimed
Bristol Myers Squibb
Chipscreen Biosciences
Citius Pharma
CSPC
CStone Pharmaceuticals
Daiichi-Sankyo
Dizal Pharma
Eisai
Genor Biopharma
Innate Pharma
Kyowa Kirin
Merck & Co
Pfizer
Roche
Seagen
Secura Bio
Shanghai Junshi Bio
Solasia
Takeda
Viracta
Table of Contents
Table
Figures
Frequently asked questions
-
What was the global TCL market size in 2020?
The global TCL market size was valued at $956 million in 2020.
-
What is the TCL market growth rate?
The global TCL market is projected to grow at a CAGR of more than 6% during the forecast period.
-
Which are the key countries in the TCL market?
The key countries in the TCL market are the US, 5EU countries, Japan, and China.
-
Who are the key players in the TCL market?
Some of the key players in the TCL market are 4SC, Acrotech Biopharma, Affimed, Bristol Myers Squibb, Chipscreen Biosciences, Citius Pharma, CSPC, CStone Pharmaceuticals, Daiichi-Sankyo, Dizal Pharma, Eisai, Genor Biopharma, and Innate Pharma.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.